ENTITY

Neurocrine Biosciences (NBIX US)

29
Analysis
Health Care • United States
Neurocrine Biosciences, Inc. is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. The Company is developing therapeutic interventions for anxiety, depression, Alzheimer's disease, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity, and diabetes.
more
bullish•S&P 500 INDEX
•22 Jul 2020 21:34

U.S. Equity Strategy: Bullish Outlook Intact

With the S&P 500 breaking above the June highs and the Russell 2000 bullishly inflecting topside a ~1-month base, it signals a continuation of...

Logo
464 Views
Share
bearish•S&P 500 INDEX
•20 May 2020 07:34

U.S. Equity Strategy: Round Trip Back To Resistance

Our base case continues to be for near-term consolidation while the market determines the implications of states’ reopening (i.e., the...

Logo
354 Views
Share
bullish•S&P 500 INDEX
•28 Nov 2019 06:30

U.S. Equity Strategy: Upgrading Health Care to Overweight

Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year...

Logo
478 Views
Share
bullish•S&P 500 INDEX
•20 Sep 2017 22:37

Vermilion Macro Vision - U.S. Equity Strategy: Sector Commentaries with Recommendations

Our last strategy “Fake Moves” highlighted our view that the markets were showing no parallel to the “fake news” narrative and indeed provided a...

Logo
501 Views
Share
bullish•S&P 500 INDEX
•06 Sep 2017 23:22

U.S. Equity Strategy: Reiterating Biotechs, Gold Miners; Downgrading Financials to Market Weight

Key themes: Downgrading Financials. Given the Sector’s relative deterioration, we are downgrading Financials to market weight. Pockets of strength...

Logo
563 Views
Share
x